Enhancing immunotherapy effectiveness for triple negative breast cancer
Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer
This study is looking at how a special protein called TFEB can help make immunotherapy work better for people with triple negative breast cancer, which is a tough type of cancer that doesn't always respond well to current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Promilead, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11065977 on NIH RePORTER |
What this research studies
This research investigates how activating a specific protein, TFEB, can improve the effectiveness of immunotherapy treatments for patients with triple negative breast cancer (TNBC). TNBC is known for being particularly aggressive and often does not respond well to existing immunotherapy options. The researchers aim to combine chemotherapy with immunotherapy to enhance the immune response against the cancer. By understanding how TFEB can modify the tumor environment and immune cell behavior, the goal is to develop a more effective treatment strategy for TNBC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are seeking new treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with triple negative breast cancer by making immunotherapy more effective.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy responses through similar approaches, indicating potential for success in this area.
Where this research is happening
Columbia, United States
- Promilead, LLC — Columbia, United States (Active)
Researchers
- Principal investigator: Fan, Daping — Promilead, LLC
- Study coordinator: Fan, Daping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.